ReachMD CME

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Understanding-Endocrine-Resistance-in-HR-HER2-mBC/37323/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-inhibition-in-HR-HER2-mBC-Mechanistic-Insights/37329/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Case-in-Point-Applying-PI3K-Combinations-in-Early-Recurrent-HR-HER2-mBC/37336/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-Inhibitors-Safety-and-Tolerability-Profiles/37338/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-managing-adult-and-pediatric-patients-with-fsgs-latest-data/37186/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/fsgs-when-solutions-fall-short/37183/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/current-fsgs-treatment-landscape-more-questions-than-answers/37184/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/monitoring-fsgs-traditional-and-novel-biomarkers/37187/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/deara-versus-soc-in-fsgs-management-clinical-trial-insights/37188/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-considerations-for-pediatric-patients-with-fsgs/37189/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-the-patient-voice-in-fsgs-management/37190/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/future-directions-in-fsgs-care/37191/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Clinical-and-Safety-Outcomes-from-the-LIGHTSITE-III-Trial/35946/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Anatomical-Outcomes-from-the-LIGHTSITE-III-Trial/35947/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Sustaining-Visual-Benefits-of-Photobiomodulation-in-Dry-Age-Related-Macular-Degeneration/35948/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Best-Practices-for-Optimized-Photobiomodulation-Treatment-Effect-Candidate-Selection/35949/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Patient-Centered-Care-and-Integration-of-Photobiomodulation-Therapy-into-Clinical-Practice/35950/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Integration-of-Photobiomodulation-Therapy-into-the-Age-Related-Macular-Degeneration-Treatment-Landscape/35951/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Real-World-Evidence-of-Photobiomodulation-Efficacy-in-Ocular-Indications/35952/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

CME credits: 1.00 Valid until: 12-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/collaborative-care-for-crswnp-expert-and-patient-insights/36695/ Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join our discussion between patients with CRSwNP and leading experts in ENT, allergy, and pulmonary medicine as they: Breakdown how to recognize key inflammatory patterns. Discuss the burden of illness and goals of treatment Interpret clinical trial data on biologic treatments. Apply a collaborative care approach to improve patient outcomes. Watch now to explore cases with patient panelists, expert perspectives, and evidence-based strategies for managing CRSwNP in multidisciplinary settings. =

CME credits: 0.50 Valid until: 02-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Insights-and-Updates-New-Data-on-Next-Generation-Retinal-Treatments/36107/ Need to catch up on the latest data surrounding next-generation retinal treatments? Drs. Veeral Sheth and Durga Borkar walk through the most recent efficacy and safety data around faricimab, aflibercept 8 mg, and the PDS with ranibizumab. They also review the latest insights on the use of these treatments in real-world practice. =

CME credits: 0.25 Valid until: 02-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Retina-Case-Review-Translating-the-Data-Into-Care/36108/ Wondering how your practice's use of next-generation retinal agents compares to the experts? Join Dr. Durga Borkar and Dr. Veeral Sheth as they discuss how they are using next-generation agents to free their patients from frequent office visits. =

CME credits: 0.25 Valid until: 29-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/global-perspectives-on-perioperative-immunotherapy-in-la-hnscc/36261/ Join our experts as they examine the integration of perioperative immune checkpoint inhibitors (ICIs) in the management of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC). Drs. Le Tourneau and Harrington discuss unmet needs and limitations of current treatment and review data from trials supporting the use of perioperative ICIs, emphasizing their event-free survival and pathologic response outcomes. The conversation also addresses multidisciplinary coordination and considerations for managing immune-related adverse events. Variations in treatment guidelines, access, and clinical practice between the US, Europe, and other regions are explored to contextualize the challenges of global implementation and provide strategies for practitioners to improve care. =

CME credits: 1.00 Valid until: 28-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-neuropsychiatric-symptoms-of-alzheimers-disease-early-recognition-diagnosis-and-innovative-emerging-therapies/35728/ Neuropsychiatric symptoms (NPS) associated with Alzheimer's disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. This broadcast replay will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.=

CME credits: 0.25 Valid until: 27-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-igan-care-achieving-lower-proteinuria-targets-with-combination-therapy/26631/ In this episode of Clinical Countdown, Professors Jonathan Barratt and Sydney Tang discuss the evolving treatment strategies for IgA nephropathy, focusing on lowering proteinuria through combination therapy. They examine differences in disease presentation across global populations and emphasize updated KDIGO guidance on aggressive proteinuria reduction targets. The discussion includes evidence from the PROTECT trial supporting sparsentan's efficacy as a dual endothelin–angiotensin receptor antagonist and considers the role of SGLT2 inhibitors based on outcomes from the DAPA-CKD and EMPA-KIDNEY trials. Our experts also review recent real-world data showing that when added to SGLT2 inhibitors and RAS blockade, sparsentan can significantly reduce proteinuria without notable safety concerns.=

CME credits: 0.25 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/resectable-head-neck-cancer-a-team-based-approach-to-perioperative-immunotherapy/35705/ Join our expert panel as they explore the evolving treatment landscape of resectable locally advanced head and neck squamous cell carcinoma. Learn how perioperative immune checkpoint inhibitors are improving event-free survival and get practical insights on applying this data to clinical care. The discussion highlights the importance of early multidisciplinary collaboration and offers perspectives on patient selection, treatment timing, and managing adverse events. Don't miss this opportunity to enhance your approach to reducing recurrence and disease progression in your patients.=

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-landscape-of-resectable-locally-advanced-hnscc/36576/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/rationale-for-combining-radiation-and-immunotherapy-in-resectable-locally-advanced-hnscc/36592/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-for-perioperative-icis-in-locally-advanced-hnscc/36593/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-and-patient-selection-for-perioperative-icis/36633/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/applying-perioperative-icis-in-clinical-practice/36634/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-in-the-perioperative-setting/36635/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/multidisciplinary-collaboration-facilitates-multimodality-therapy/36636/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.50 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/risk-reduction-with-glp-1-ras-in-individuals-with-ascvd-and-t2d-2025-update/36474/ Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many individuals with type 2 diabetes are reluctant to initiate or refuse injectable therapy. Oral GLP-1 RA therapy has demonstrated robust reductions in A1C and in body weight; in addition, the cardiovascular safety of oral GLP-1 RA therapy has been established in individuals with T2D and high cardiovascular risk. Until recently, there has been an unmet need to determine the cardiovascular efficacy of this oral therapy in patients at high cardiovascular risk—for example, in those individuals with ASCVD, CKD, or both. Dr. Silvio Inzucchi and Dr. Darren McGuire will review trials with injectable GLP-1 RAs in individuals with T2D and high ASCVD risk, and discuss the recent clinical trial evidence in this population with oral GLP-1 RA therapy and the implications for patient management. =

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/why-celmods-matter-in-myeloma/36558/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/molecular-magic-decoding-the-unique-mechanism-of-celmods/36562/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/data-dive-clinical-evidence-behind-celmods/36568/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-targeting-matching-celmods-to-the-right-patient-with-myeloma/36569/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.